Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Tonix Pharma ( (TNXP) ) has provided an announcement.
The Company has unveiled promising preclinical results for its TNX-801 vaccine candidate at the World Vaccine Congress-Europe 2024, showcasing its safety and efficacy even in immunocompromised animals. This novel, single-dose vaccine does not spread in blood or tissues, even at doses much higher than traditional vaccines, sparking interest among investors for its potential market impact. However, forward-looking statements highlight uncertainties and risks, urging investors to tread carefully.
Find detailed analytics on TNXP stock on TipRanks’ Stock Analysis page.
